Fig. 7

Risk score is a potential biomarker to predict benefits from immune therapies in STAD. A TIDE predicted the proportion of patients with response to immunotherapy in low-risk and high-risk groups. B The proportion of patients with response to immunotherapy in low-risk and high-risk groups in the PRJEB25780 immunotherapy cohort (45 patients with advanced gastric cancer who had received PD-L1 inhibitor treatment). C TIDE predicted the proportion of patients with response to immunotherapy in low-immune score and high-immune score groups. D TIDE predicted the proportion of patients of four groups based on the risk score and immune score with response to immunotherapy. E TIDE predicted the proportion of patients with response to immunotherapy in low-stromal score and high-stromal score groups. F TIDE predicted the proportion of patients of four groups based on the risk score and immune score with response to immunotherapy. G TIDE predicted the proportion of patients with response to immunotherapy in MSS, MSI-L and MSI-H groups. H TIDE predicted the proportion of patients of six groups based on the risk score and microsatellite status with response to immunotherapy. MSS, Microsatellite stability; MSI-L, Microsatellite Instability-Low; MSI-H, Microsatellite Instability-High. P values were showed as: ns not significant; ***P < 0.001